临床衰弱增加胸腹主动脉瘤F/BEVAR术后主动脉相关死亡风险
单中心2012至2024年233例胸腹主动脉瘤行开窗/分支血管腔内修复(F/BEVAR)患者中,术前临床衰弱量表(CFS)≥4分者占25.8%。衰弱组围手术期并发症无差异,但住院更长、恢复术前功能状态更少,远期生存更差且主动脉相关死亡更高。
要点
- 术前CFS≥4与F/BEVAR术后远期生存降低独立相关
- 衰弱组主动脉相关死亡、肺部合并症、感染及全身衰退死亡更多
- 建议F/BEVAR术前评估表型衰弱以辅助患者咨询
核心结论
- 临床衰弱与胸腹主动脉瘤F/BEVAR术后长期生存降低及主动脉相关死亡风险增加相关。
- 慢性疾病负担是总体死亡的主要驱动因素,衰弱患者更易死于肺部合并症、感染和全身衰退。
研究设计与样本
- 单中心回顾性队列研究,纳入2012至2024年接受F/BEVAR的胸腹主动脉瘤患者233例。
- 以临床衰弱量表(CFS)评估表型衰弱,CFS≥4为衰弱组(60例,25.8%),CFS<4为非衰弱组(173例,74.2%)。
主要发现
- 衰弱组慢性阻塞性肺疾病比例更高(53% vs 27%),动脉瘤直径稍大(72 mm vs 68 mm;P = .04)。
- 两组围手术期并发症包括30天死亡率、卒中和脊髓缺血无差异。
- 衰弱组住院时间更长(11.3天 vs 6.9天;P < .01),恢复术前功能状态比例更低(62.7% vs 86.1%;P < .01)。
- 衰弱组1年、3年、5年生存率更低(74% vs 89%、39% vs 73%、25% vs 56%;P < .01)。
- 衰弱组主动脉相关死亡更高(10.3% vs 5.9%;P = .02),肺部合并症(15.4% vs 13.2%;P = .04)、全身衰退(7.7% vs 1.5%;P = .02)和感染(12.8% vs 7.4%;P = .03)死亡亦更高。
关键数值与推荐
- 全队列3年全因死亡率和主动脉相关死亡率分别为35.2%和5.7%。
- 全队列1年和3年主动脉相关死亡率分别为2.2%和5.7%。
- 两组最常见死因均为肺部合并症(14.0%)、肿瘤(14.0%)、心血管合并症(11.2%)和手术相关并发症(11.2%)。
临床怎么用
- F/BEVAR术前应考虑进行表型衰弱评估以辅助患者咨询和决策。
- 对CFS≥4的衰弱患者,应充分告知其远期生存降低及主动脉相关死亡风险增加。
局限性
- 单中心回顾性设计可能限制结果外推。
- 原文未报告多变量校正后衰弱与结局的独立关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinical frailty is associated with reduced long-term survival after fenestrated and branched endovascular aortic repair (F/BEVAR). This study assesses the impact of phenotypic clinical frailty on perioperative outcomes and cause of death following F/BEVAR for thoracoabdominal aortic aneurysm. METHODS: Patients who underwent F/BEVAR at a single institution from 2012 to 2024 were identified. The clinical frailty scale (CFS) was used to determine phenotypic frailty. Patients with a preoperative CFS of ≥4 (vulnerable) and a CFS of <4 were compared. We used χ2 and Fischer exact tests to compare patient demographics, anatomical and operative characteristics, and perioperative outcomes. Fine-Gray analysis was used to compare cause of death between groups. Long-term survival and reintervention were assessed with Kaplan-Meier and Cox regression analyses. RESULTS: We included 233 patients; 60 (25.8%) had a CFS of ≥4 and 173 (74.2%) had a CFS of <4. Patients with a CFS of ≥4 were more likely to have chronic obstructive pulmonary disease (53% vs 27%) and were treated for slightly larger aneurysms (72 mm vs 68 mm; P = .04). There were no differences in symptomatic presentation, aneurysm extent, or operative complexity between patient groups. Additionally, there were no differences in perioperative complications including 30-day mortality, stroke, and spinal cord ischemia. Patients with a CFS of ≥4 had an increased length of hospitalization (11.3 days vs 6.9 days; P < .01) and were less likely to return to preoperative functional status (62.7% vs 86.1%; P < .01). The 3-year all-cause and aortic-related mortality rates were 35.2% and 5.7%, respectively. Patients with a CFS of ≥4 had a lower survival at 1 year (74% vs 89%), 3 years (39% vs 73%), and 5 years (25% vs 56%), compared with patients with a CFS of <4 (P < .01). The most common causes of death among both groups were pulmonary comorbidities (14.0%), oncologic conditions (14.0%), cardiovascular comorbidities (11.2%), and procedure-related complications (11.2%). Patients with a CFS of ≥4 were more likely to die from aortic-related mortality (10.3% vs 5.9%; P = .02), pulmonary comorbidities (15.4 vs 13.2%; P = .04), systemic decline (7.7% vs 1.5%; P = .02), and infection (12.8% vs 7.4%; P = .03). Aortic-related mortality for the entire patient cohort was 2.2% and 5.7% at 1 year and 3 years, respectively. Aortic-related deaths among clinically frail patients were often due to an inability to tolerate further aortic operations (eg, arch repair), and secondary to follow-up nonadherence in patients with a CFS of <4. CONCLUSIONS: In an expanded cohort of patients, clinical frailty was associated with lower long-term survival and an increased risk for aortic-related mortality after F/BEVAR for the treatment of thoracoabdominal aortic aneurysms. Chronic disease burden is a primary driver of overall mortality, and clinically frail patients are more likely to die from pulmonary comorbidities, infection, and systemic decline. Phenotypic frailty assessment should be considered in preoperative assessment and patient counseling before F/BEVAR.
引用
- Chen S, Ramirez E, Murphy BE, et al. Increased clinical frailty is associated with aortic-related mortality following fenestrated and branched endovascular repair for thoracoabdominal aortic aneurysm. J Vasc Surg. 2025. PMID: 41101709. doi:10.1016/j.jvs.2025.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。